The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Abstract
The benefits of modelling and simulation at the pre-clinical stage of drug development can be realized through formal and realistic integration of data on physicochemical properties, pharmacokinetics, pharmacodynamics, formulation and safety. Such data integration and the powerful combination of physiologically based pharmacokinetic (PBPK) with pharmacokinetic-pharmacodynamic relationship (PK/PD) models provides the basis for quantitative outputs allowing comparisons across compounds and resulting in improved decision-making during the selection process. Such PBPK/PD evaluations provide crucial information on the potency and safety of drug candidates in vivo and the bridging of the PK/PD concept established during the pre-clinical phase to clinical studies. Modelling and simulation is required to address a number of key questions at the various stages of the drug-discovery and -development process. Such questions include the following. (1) What is the expected human PK profile for potential clinical candidate(s)? (2) Is this profile and its associated PD adequate for the given indication? (3) What is the optimal dosing schedule with respect to safety and efficacy? (4) Is a food effect expected? (5) How can formulation be improved and what is the potential benefit? (6) What is the expected variability and uncertainty in the predictions?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
Self-citation(2024) · Pharmacological Reviews · doi:10.1124/pr · Cited by 2,680
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Ito, K., Iwatsubo, T., Kanamitsu, S.-I., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 511
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
Self-citationDiversity of Mechanism-Based Pharmacodynamic Models
Mager, D. E., Wyska, E., & Jusko, W. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.510 · Cited by 345
Comparison of Canine and Human Gastrointestinal Physiology
Dressman, J. (1986) · Pharmaceutical Research · doi:10.1023/a:1016353705970 · Cited by 339
Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices
Houston, J. B., & Carlile, D. J. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709002237 · Cited by 304
Whole Body Pharmacokinetic Models
Nestorov, I. A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342100-00002 · Cited by 290
Paulson, S. K., Vaughn, M. B., Jessen, S. M., Lawal, Y. M., Gresk, C. J., Yan, B., Maziasz, T. J., Cook, C. S., & Karim, A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29580-x · Cited by 288
Tucker, G. T., Houston, J. B., & Huang, S. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Ito, K., Iwatsubo, T., Kanamitsu, S.-I., Nakajima, Y., & Sugiyama, Y. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
Willmann, S., Höhn, K., Edginton, A. N., Sevestre, M., Solodenko, J., Weiß, W. W., Lippert, J., & Schmitt, W. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9053-5 · Cited by 258
Danhof, M., DeJongh, J., de Lange, E. C. M., Pasqua, O. E. D., Ploeger, B. A., & Voskuyl, R. A. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105154 · Cited by 258
Rostami‐Hodjegan, A., & Tucker, G. T. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 242
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2004) · Xenobiotica · doi:10.1080/00498250310001646353 · Cited by 219
Population pharmacokinetic studies in pediatrics: Issues in design and analysis
Meibohm, B., Läer, S., Panetta, J. C., & Barrett, J. S. (2005) · The AAPS Journal · doi:10.1208/aapsj070248 · Cited by 193
Whole-body physiologically based pharmacokinetic models
Nestorov, I. A. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.235 · Cited by 188
Jones, H. M., Parrott, N. J., Ohlenbusch, G., & Lav, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00006 · Cited by 150
Self-citationLumping of Whole-Body Physiologically Based Pharmacokinetic Models
Nestorov, I. A., Aarons, L. J., Arundel, P. A., & Rowland, M. (1998) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1023272707390 · Cited by 132
Rowland, M., Balant, L., & Peck, C. C. (2004) · AAPS PharmSci · doi:10.1208/ps060106 · Cited by 131
Parrott, N., Paquereau, N., Coassolo, P., & Lavé, T. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20419 · Cited by 107
Self-citationAndersen, M. E. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03355-o · Cited by 94
Parrott, N. J., Jones, H. M., Paquereau, N., & Lavé, T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960308.x · Cited by 93
Self-citationPrediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences
Inoue, S., Howgate, E. M., Rowland‐Yeo, K., Shimada, T., Yamazaki, H., Tucker, G. T., & Rostami‐Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683262 · Cited by 91
Rowland, M., Balant, L., & Peck, C. C. (2004) · Research Explorer (The University of Manchester) · Cited by 82
Physiologic pharmacokinetic models and interanimal species scaling
Rowland, M. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90016-6 · Cited by 80
Applying Simulation Modeling to Problems in Toxicology and Risk Assessment: A Short Perspective
Andersen, M. E., M.A., H. J. C. I., & Frederick, C. B. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1140 · Cited by 73
Brightman, F. A., Leahy, D. E., Searle, G. E., & Thomas, S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004804 · Cited by 67
Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics
Nestorov, I. A. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00273-9 · Cited by 57
Lüpfert, C., & Reichel, A. (2005) · Chemistry & Biodiversity · doi:10.1002/cbdv.200590119 · Cited by 56
Brightman, F. A., Leahy, D. E., Searle, G. E., & Thomas, S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004838 · Cited by 53
Gueorguieva, I., Nestorov, I. A., & Rowland, M. (2005) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-005-0004-8 · Cited by 50
Gueorguieva, I., Nestorov, I. A., & Rowland, M. (2004) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/b:jopa.0000039564.35602.78 · Cited by 47
Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics
Houston, J. B. (1994) · Toxicology in Vitro · doi:10.1016/0887-2333(94)90002-7 · Cited by 44
Preclinical Development Handbook
(2007) · Wiley eBooks · doi:10.1002/9780470249055 · Cited by 39
Kansal, A. R., & Trimmer, J. (2005) · IEE Proceedings - Systems Biology · doi:10.1049/ip-syb:20050043 · Cited by 32
Gueorguieva, I., Aarons, L. J., & Rowland, M. (2006) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-006-9023-3 · Cited by 30
Andersen, M. E. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03487-0 · Cited by 26
Evaluation of Methods for Predicting Drug-drug Interactions by Monte Carlo Simulation
Kato, M., Tachibana, T., Ito, K., & Sugiyama, Y. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.121 · Cited by 26
Predictive biosimulation and virtual patients in pharmaceutical R and D.
Bangs, A. (2005) · PubMed · Cited by 22
The impact of systems biology and biosimulation on drug discovery and development
Michelson, S. (2006) · Molecular BioSystems · doi:10.1039/b602194h · Cited by 22
Drug discovery information integration: virtual humans for pharmacokinetics
Leahy, D. E. (2004) · Drug Discovery Today BIOSILICO · doi:10.1016/s1741-8364(04)02394-7 · Cited by 20
ASSESSING THE IMPACT OF PREDICTIVE BIOSIMULATION ON DRUG DISCOVERY AND DEVELOPMENT
Michelson, S. (2003) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720003000022 · Cited by 15
BME company profiles entelos: predictive model systems for disease
Demir, S. S., & Stokes, C. (2005) · IEEE Engineering in Medicine and Biology Magazine · doi:10.1109/memb.2005.1436439 · Cited by 2
Research works printed but not linked: 2
- Bangs A, 2005, Studies in Health Technology Information, 111, 37
- Jones HM, 2005, Paper presented at the PAGE 16th Conference 2005
Cited by
Sorted by citations
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
Self-citationComputational Approaches in Preclinical Studies on Drug Discovery and Development
Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00726 · Cited by 494
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S. B., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 447
Metadata
- Authors
- Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Roche (United States) (US)
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2007-11
- Volume
- 37
- Issue
- 10-11
- Pages
- 1295-1310
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W1994206407
- Cited by
- 115
- References
- 47
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 11 · 2013: 6 · 2012: 9
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- modeling and simulation, drug discovery, drug development, physiologically based pharmacokinetic modeling, pharmacokinetic-pharmacodynamic modeling, dosing schedule optimization, food effect, drug formulation, interindividual variability, forecast uncertainty, drug candidate selection
- MeSH terms
- Absorption, Animals, Biological Transport, Active, Drug Interactions, Food, Humans, Models, Biological, Drug Design, Xenobiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
